文献速递血液淋巴病理

二代测序用于淋巴系统肿瘤:临床检测的真实世界效用

Next-generation sequencing for lymphoid neoplasms: Real-world utility from a clinical assay.
PubMed 文献 · Hum Pathol · 2026-04-12

该研究回顾性分析了384例淋巴系统肿瘤二代测序(LNGS)检测案例,涵盖限制性B细胞淋巴瘤panel(25基因)、扩展性B细胞淋巴瘤panel(46基因)和T细胞淋巴瘤panel(22基因)。结果显示64.6%的病例检出至少一个突变,59.4%的突变具有预后价值,32.6%的检测提供了治疗反应或耐药的预测价值,9.4%的检测提供了诊断价值。LNGS在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)和套细胞淋巴瘤(MCL)中预后价值最明显,在血管免疫母细胞性T细胞淋巴瘤和毛细胞白血病中诊断价值突出,在淋巴浆细胞淋巴瘤中具有诊疗一体化价值,在滤泡性淋巴瘤和T/NK细胞大颗粒淋巴细胞白血病中兼具诊断和预后价值。

要点

  • LNGS在多数病例中可提供预后和预测信息,有助于优化临床管理。
  • CLL/SLL和MCL中LNGS的预后价值最突出。
  • 血管免疫母细胞性T细胞淋巴瘤和毛细胞白血病中LNGS诊断价值明显。

核心结论

  • 精心设计并选择性开具的LNGS检测多数可提供预后和预测数据,辅助临床管理优化。
  • LNGS的诊断价值可能随着其进一步使用和可及性提高而增加。

研究设计与样本

  • 回顾性研究,共纳入384例病例,结合病理报告进行分析。
  • 121例检测限制性B细胞淋巴瘤panel(25基因),183例检测扩展性B细胞淋巴瘤panel(46基因),80例检测T细胞淋巴瘤panel(22基因)。
  • 标本类型包括骨髓170例(44.3%)、外周血120例(31.3%)和福尔马林固定石蜡包埋组织93例(24.2%)。

主要发现

  • 248/384(64.6%)例检出至少一个突变;排除已知淋巴瘤阴性标本后,245/347(70.6%)例检出突变。
  • 最常见的淋巴瘤类型为CLL/SLL(40.6%)和MCL(9.6%)。
  • 228/384(59.4%)例检出具有预后价值的突变。
  • 125例(32.6%)检测提供了对特定治疗反应或耐药的预测价值。
  • 36例(9.4%)检测提供了诊断价值,帮助病理医生分类疾病或作出更明确的诊断。

临床怎么用

  • LNGS结果在CLL/SLL和MCL中主要用于预后判断。
  • 在血管免疫母细胞性T细胞淋巴瘤和毛细胞白血病中,LNGS具有诊断价值。
  • 在淋巴浆细胞淋巴瘤中,LNGS具有诊疗一体化价值。
  • 在滤泡性淋巴瘤和T/NK细胞大颗粒淋巴细胞白血病中,LNGS兼具诊断和预后价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although next-generation sequencing (NGS) has become the standard of care in myeloid neoplasms, the utility of lymphoma NGS (LNGS) in the clinical setting has not been well established. The goal of this study was to document the real-world use of LNGS panels and assess their prognostic, predictive, and diagnostic value. A total of 384 cases were retrospectively reviewed in conjunction with pathology reports, including 121, 183, and 80 tested for the limited B-cell lymphoma panel (25 genes), expanded B-cell lymphoma panel (46 genes), or T-cell lymphoma panel (22 genes), respectively. Specimen types included 170 (44.3%) bone marrow, 120 (31.3%) peripheral blood, and 93 (24.2%) formalin-fixed paraffin-embedded tissue. 248/384 (64.6%) cases showed at least one mutation; 245/347 (70.6%) when excluding specimens known to be negative for lymphoma. Chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL/CLL, 40.6%) and mantle cell lymphoma (MCL, 9.6%) were the most common lymphoma types tested. Mutations with prognostic value were found in 228/384 (59.4%) cases. 125 (32.6%) tests provided predictive value for response or resistance to a specific therapy. 36 tests (9.4%) provided diagnostic value, aiding the pathologist in classifying disease or rendering a more definitive diagnosis. LNGS results are most useful as being prognostic in CLL/SLL and MCL, diagnostic in angioimmunoblastic T-cell lymphoma and hairy cell leukemia, theranostic in lymphoplasmacytic lymphoma, and diagnostic and prognostic in follicular lymphoma and T/NK-cell large granular lymphocytic leukemia. Although clinical guidelines have not yet widely incorporated LNGS, when carefully designed and selectively ordered by clinicians and pathologists, the majority of tests do offer prognostic and predictive data which can aid in optimization of clinical management. The diagnostic value of LNGS testing is likely to increase with its further use and availability.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Chen C, Artymiuk CJ, Schwab TL, et al. Next-generation sequencing for lymphoid neoplasms: Real-world utility from a clinical assay. Hum Pathol. 2026. PMID: 41974312. doi:10.1016/j.humpath.2026.106123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。